drugset / Trial / NCT05816252
A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)
Phase 2
Active not recruiting
356 enrolled
Klus Pharma Inc.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability and objective response rate of SKB264 as combination with therapy in subjects with advanced or metastatic non-small cell lung cancer.
Timeline
- Start
- 2023-04-19
- Primary completion
- 2026-06-30
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sacituzumab Tirumotecan | Other / unclassified | — | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Osimertinib | Small molecule | 80 mg | — |
| Background | Pembrolizumab | Monoclonal antibody | 400 mg | Intravenous |